StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Earnings

BioCryst Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$180.30M
+13.1% on a year earlier
Adjusted EPS, Q3 FY2026
$0.14
$0.16 a year earlier
Latest guidance
Raised
Nov 4, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of BioCryst Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026before the open$180.30M+13.1%$0.14–Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$218.30M+33.6%$0.30–Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open––––Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$406.56M+209.2%$1.12–Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025before the open$159.40M+36.1%$0.06$0.16Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025before the open$163.40M+49.5%$0.02$0.15Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$145.50M+56.8%$0.00–Release
Q4 FY2024ended Dec 31, 2024Feb 24, 2025before the open$131.50M+40.8%-$0.13-$0.13Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024before the open$117.10M+35.1%-$0.07-$0.07Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024before the open$109.30M+32.5%-$0.06-$0.06Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$92.80M+34.9%-$0.17-$0.17Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BioCryst Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
ORLADEYO revenueFY2026$625.00M – $645.00M$625.00M – $645.00MLoweredAug 5, 2026
total revenue outlookFY2026$715.00M – $730.00M$625.00M – $645.00MRaisedNov 4, 2026
global net ORLADEYO revenueFY2026$625.00M – $645.00M–NewNov 4, 2026
Non-GAAP operating expense including Astria acquisitionnon-GAAPFY2026$450.00M – $470.00M–RaisedJan 12, 2026
non-GAAP operating expensesnon-GAAPFY2026$415.00M – $425.00M$450.00M – $470.00MLoweredNov 4, 2026
non-GAAP operating expensesnon-GAAPFY2026$420.00M – $440.00M$450.00M – $470.00MLoweredAug 5, 2026
non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costsnon-GAAPFY2026$380.00M – $390.00M–NewJan 12, 2026

Guidance history

Every forecast BioCryst Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026global net ORLADEYO revenueFY2026$625.00M – $645.00MNew
Nov 4, 2026non-GAAP operating expensesFY2026$415.00M – $425.00MLowered
Nov 4, 2026total revenue outlookFY2026$715.00M – $730.00MRaised
Aug 5, 2026non-GAAP operating expensesFY2026$420.00M – $440.00MLowered
Aug 5, 2026ORLADEYO revenueFY2026$625.00M – $645.00MLowered
Aug 5, 2026total revenueFY2026$690.00M – $715.00MRaised
May 6, 2026non-GAAP operating expensesFY2026$450.00M – $470.00MReaffirmed
May 6, 2026ORLADEYO revenueFY2026$625.00M – $645.00MLowered
May 6, 2026total revenueFY2026$635.00M – $660.00MRaised
Feb 26, 2026non-GAAP operating expensesFY2026$450.00M – $470.00MNew
Feb 26, 2026global net ORLADEYO revenueFY2026$625.00M – $645.00MNew
Feb 26, 2026total revenue, including RAPIVAB® (peramivir injection)FY2026$635.00M – $660.00MRaised
Jan 12, 2026non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costsFY2026$380.00M – $390.00MNew
Jan 12, 2026Non-GAAP operating expense including Astria acquisitionFY2026$450.00M – $470.00MRaised
Jan 12, 2026ORLADEYO revenueFY2026$625.00M – $645.00MNew
Jan 12, 2026total revenue, including RAPIVAB® (peramivir injection)FY2026$635.00M – $660.00MRaised
Nov 3, 2025non-GAAP operating expensesFY2025$430.00M – $440.00MLowered
Nov 3, 2025global net ORLADEYO revenueFY2025$590.00M – $600.00MRaised
Aug 4, 2025non-GAAP operating expensesFY2025$440.00M – $450.00MReaffirmed
Aug 4, 2025global net ORLADEYO revenueFY2025$580.00M – $600.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases BioCryst Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Update
  6. Results
  7. Update
  8. Update
  9. Update
  10. Results
  11. News
  12. News
  13. Results
  14. Results
  15. Results

See a number that looks wrong?